Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared a post on LinkedIn:
“When I follow news of ELCC 2026, I found myself thinking about how far we’ve come in thoracic oncology.
Not long ago, rare thoracic tumors felt like a space of limited options… limited evidence… and many unanswered questions.
But this year felt different.
- I saw HER2-mutant NSCLC responding in ways we couldn’t expect before.
- I saw KRAS G12D, once labeled “undruggable,” finally being challenged.
- I saw smarter strategies emerging for high-risk EGFR, where biology is no longer a barrier—but a guide.
Even in mesothelioma and thymic tumors, there is a quiet but real shift toward targeted approaches. It’s no longer about ‘rare’ cancers. It’s about precise biology… and how well we understand it.
The real progress is not just new drugs-it’s a new mindset.”
Other articles about thoracic oncology on OncoDaily
